AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37355803 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Group (BHG) - an attention control condition focused on brain health education and self-management.
Number of subjects: 0
Study 37355803 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Group (BHG)
Number of subjects: 0
Study 37356033 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg pegozafermin weekly
Number of subjects: 222
Study 37356033 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pegozafermin weekly
Number of subjects: 222
Study 37356033 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 mg pegozafermin once every 2 weeks
Number of subjects: 222
Study 37356033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 37356038 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab (5 mg/kg) plus standard of care
Number of subjects: 422
Study 37356038 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 422
Study 37356066 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 984
Study 37356066 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 984
Study 37356066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinically significant or severe hypoglycemia with insulin icodec
Number of subjects: 984
Study 37356066 — intervention group
Group type: COMPARATOR
Intervention: Combined clinically significant or severe hypoglycemia with insulin glargine U100
Number of subjects: 984
Study 37356075 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 272
Study 37356075 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 272
Study 37356075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 37356078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib as a fourth-line treatment
Number of subjects: 240
Study 37356256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (open-label, single-arm, multicenter, phase IV study)
Number of subjects: 182
Study 37356492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanalicular Dexamethasone Insert
Number of subjects: 0
Study 37356492 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37356500 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal preconception BMI (mean 23.6, SD 4.4)
Number of subjects: 4733
Study 37356515 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Physical Anhedonia Scale (PAS) scores
Number of subjects: 98
Study 37356515 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Inventory for Depressive Symptoms (IDS) scores
Number of subjects: 98
Study 37356549 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sulfur amino acids (TSAA) requirement in older men
Number of subjects: 0
Study 37356549 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sulfur amino acids (TSAA) requirement in older women
Number of subjects: 0
Study 37356561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge containing Lacticaseibacillus rhamnosus, LGG® (DSM33156), Lactobacillus paracasei subsp. paracasei, L. CASEI 431® (DSM33451) and prebiotic (arginine 2%)
Number of subjects: 343
Study 37356561 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge without arginine or probiotics
Number of subjects: 343
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset chronic pain
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary pain
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chronic pain
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on daily life
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Associated conditions
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation
Number of subjects: 143
Study 37356618 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized pain centre follow-up
Number of subjects: 143
Study 37356632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) application, 1.25 g of TXA powder sprayed endoscopically on the ulcer, alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Number of subjects: 60
Study 37356632 — intervention group
Group type: COMPARATOR
Intervention: Standard group (no TXA), alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Number of subjects: 60
Study 37356632 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) application
Number of subjects: 60
Study 37356632 — intervention group
Group type: COMPARATOR
Intervention: Standard group (no TXA)
Number of subjects: 60
Study 37356634 — intervention group
Group type: EXPERIMENTAL
Intervention: US capsule endoscopy (USCE)
Number of subjects: 20
Study 37356707 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive visitation policies
Number of subjects: 0
Study 37356707 — intervention group
Group type: COMPARATOR
Intervention: Standard visitation policies
Number of subjects: 0
Study 37356708 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL ExoFlo
Number of subjects: 102
Study 37356708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 37356710 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive strategies for radiographic surveillance
Number of subjects: 2049
Study 37356710 — intervention group
Group type: COMPARATOR
Intervention: Less intensive strategies for radiographic surveillance
Number of subjects: 2049
Study 37356876 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart insulin
Number of subjects: 50
Study 37357024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 37357024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37357092 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric support for PTSD
Number of subjects: 0
Study 37357092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychiatric support)
Number of subjects: 0
Study 37357331 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina enriched crackers (35 g, twice daily for 12 weeks)
Number of subjects: 66
Study 37357331 — intervention group
Group type: COMPARATOR
Intervention: Placebo crackers (35 g, twice daily for 12 weeks)
Number of subjects: 66
Study 37357331 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina enriched crackers
Number of subjects: 66
Study 37357331 — intervention group
Group type: COMPARATOR
Intervention: Placebo crackers
Number of subjects: 66
Study 37357351 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37357807 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg iron supplements taken in the morning with ascorbic acid (AA)
Number of subjects: 34
Study 37357807 — intervention group
Group type: COMPARATOR
Intervention: 100 mg iron supplements taken at different times of day without ascorbic acid (AA)
Number of subjects: 34
Study 37357811 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated physical activity intervention (workshop group)
Number of subjects: 31
Study 37357811 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated physical activity intervention (online group)
Number of subjects: 31
Study 37357811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 37357904 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (8 mg) and Albendazole (400 mg)
Number of subjects: 210
Study 37357904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 µg/kg) and Albendazole (400 mg)
Number of subjects: 210
Study 37357904 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg) and Placebo
Number of subjects: 210
Study 37357950 — intervention group
Group type: EXPERIMENTAL
Intervention: barecetamab monotherapy at 20 mg/kg IV every 3 weeks
Number of subjects: 33
Study 37357950 — intervention group
Group type: EXPERIMENTAL
Intervention: barecetamab (20 mg/kg IV) and cetuximab (400 mg/m2) combination therapy
Number of subjects: 33
Study 37357950 — intervention group
Group type: EXPERIMENTAL
Intervention: barecetamab at 1, 3, 5, 10, and 20 mg/kg IV on days 1 and 28 and weekly
Number of subjects: 33
Study 37358048 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 98
Study 37358048 — intervention group
Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mmHg)
Number of subjects: 98
Study 37358056 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of generic 'you' in expressive writing
Number of subjects: 138
Study 37358262 — intervention group
Group type: EXPERIMENTAL
Intervention: High & Increasing MVPA
Number of subjects: 577
Study 37358262 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher MVPA level at 12-month follow-up
Number of subjects: 577
Study 37358545 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alcohol challenge
Number of subjects: 0
Study 37358545 — intervention group
Group type: COMPARATOR
Intervention: Expectancy of alcohol analgesia
Number of subjects: 0
Study 37358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib containing therapy
Number of subjects: 81
Study 37358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib after prior ibrutinib therapy
Number of subjects: 81
Study 37358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib without prior ibrutinib therapy
Number of subjects: 81
Study 37358640 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib therapy
Number of subjects: 81
Study 37358716 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-CareQOL measures
Number of subjects: 139
Study 37358858 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-course therapy (another 5 days of antimicrobials)
Number of subjects: 664
Study 37358858 — intervention group
Group type: COMPARATOR
Intervention: Short-course therapy (5 days of placebo)
Number of subjects: 664
Study 37358858 — intervention group
Group type: COMPARATOR
Intervention: Short-course therapy
Number of subjects: 664
Study 37358858 — intervention group
Group type: COMPARATOR
Intervention: Standard-course therapy and Short-course therapy
Number of subjects: 664
Study 37358859 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide (NBP)
Number of subjects: 1216
Study 37358859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1216
Study 37358870 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont-plus maneuver (SM-plus)
Number of subjects: 195
Study 37358870 — intervention group
Group type: COMPARATOR
Intervention: Epley maneuver (EM)
Number of subjects: 195
Study 37358870 — intervention group
Group type: EXPERIMENTAL
Intervention: Single maneuver performed by physician (for both groups)
Number of subjects: 195
Study 37358870 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 195
Study 37358883 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive mobile health app
Number of subjects: 59
Study 37358883 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized tunneling
Number of subjects: 59
Study 37358888 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app SidekickHealth (social health game focusing on nutrition, mental health, and physical health)
Number of subjects: 304
Study 37358888 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 304
Study 37358908 — intervention group
Group type: EXPERIMENTAL
Intervention: KeepCalm app
Number of subjects: 20
Study 37358916 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI112 (subcutaneous 5-600 mg or intravenous 100 and 600 mg)
Number of subjects: 46
Study 37358916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 37359242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 300 mg and Binimetinib 30 mg
Number of subjects: 38
Study 37359242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin 200 mg and Binimetinib 45 mg
Number of subjects: 38
Study 37359242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrastaurin and Binimetinib (combined)
Number of subjects: 38
Study 37359465 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led therapist-assisted intervention (SC TF-CBT)
Number of subjects: 0
Study 37359866 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk about Children intervention
Number of subjects: 0
Study 37359884 — intervention group
Group type: EXPERIMENTAL
Intervention: Surf Therapy
Number of subjects: 96
Study 37359884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hike Therapy
Number of subjects: 96
Study 37360058 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term intensive parent training program
Number of subjects: 111
Study 37360058 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 111
Study 37360060 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive caregiving intervention educating parents about the developing brain and alternatives to corporal punishment
Number of subjects: 153
Study 37360060 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 153
Study 37360346 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment with lipoic acid
Number of subjects: 114
Study 37360348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergotact training program
Number of subjects: 28
Study 37360348 — intervention group
Group type: COMPARATOR
Intervention: Control training group (Self)
Number of subjects: 28
Study 37360352 — intervention group
Group type: EXPERIMENTAL
Intervention: DOSE protocol (higher intensity walking)
Number of subjects: 0
Study 37360352 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (control group)
Number of subjects: 0
Study 37360762 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate Mind Training for Caregivers (CMT-Care Homes)
Number of subjects: 127
Study 37360762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 127
Study 37360811 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) intervention incorporating Japanese garden aesthetics, relaxation, and elements of Erickson's psychotherapy
Number of subjects: 60
Study 37360811 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity general fitness training sessions (twice a week for four weeks)
Number of subjects: 60
Study 37360864 — intervention group
Group type: EXPERIMENTAL
Intervention: Convidecia (heterologous third dose)
Number of subjects: 299
Study 37360864 — intervention group
Group type: EXPERIMENTAL
Intervention: Convidecia (heterologous second dose)
Number of subjects: 299
Study 37360864 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac (three doses)
Number of subjects: 299
Study 37360864 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac (second dose)
Number of subjects: 299
Study 37360864 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac (third dose)
Number of subjects: 299
Study 37361167 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal aptitudes (activation, health literacy, personality traits)
Number of subjects: 16
Study 37361203 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragali Radix
Number of subjects: 0
Study 37361203 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37361220 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 37361220 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 0
Study 37361338 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative Study Within A Trial (Qual-SWAT)
Number of subjects: 0
Study 37361343 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-level intervention
Number of subjects: 42
Study 37361343 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Number of subjects: 42
Study 37361343 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 42
Study 37361483 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiologic symptom relief therapy (PSRT) during a 13 week (approximately 44 hour) course.
Number of subjects: 23
Study 37361536 — intervention group
Group type: EXPERIMENTAL
Intervention: DiaCompanion I (intervention group)
Number of subjects: 216
Study 37361536 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 216
Study 37361617 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + ablation of EGF-identified extra-PV sources of AF
Number of subjects: 85
Study 37361617 — intervention group
Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 85
Study 37362184 — intervention group
Group type: EXPERIMENTAL
Intervention: MORE + JITAI
Number of subjects: 0
Study 37362184 — intervention group
Group type: EXPERIMENTAL
Intervention: JITAI-initiated mindfulness practice
Number of subjects: 0
Study 37362184 — intervention group
Group type: COMPARATOR
Intervention: SG (control group)
Number of subjects: 0
Study 37363124 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day Advanced Cardiac Life Support course followed by 3-day Vital Anaesthesia Simulation Training Course
Number of subjects: 47
Study 37363177 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous suicidal attempt
Number of subjects: 0
Study 37363177 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-20
Number of subjects: 0
Study 37363177 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI-13
Number of subjects: 0
Study 37363177 — intervention group
Group type: COMPARATOR
Intervention: Clinical features (alcohol dependence, suicide intent, hopelessness)
Number of subjects: 0
Study 37363177 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous SA, depression, and alexithymia
Number of subjects: 0
Study 37363275 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital assessment screening
Number of subjects: 751
Study 37363275 — intervention group
Group type: COMPARATOR
Intervention: Physical assessment screening
Number of subjects: 751
Study 37363832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy
Number of subjects: 9
Study 37363832 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass
Number of subjects: 9
Study 37363832 — intervention group
Group type: COMPARATOR
Intervention: Preoperative Baseline
Number of subjects: 9
Study 37363967 — intervention group
Group type: EXPERIMENTAL
Intervention: Laxative use
Number of subjects: 265
Study 37363967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vomiting frequency
Number of subjects: 265
Study 37363967 — intervention group
Group type: COMPARATOR
Intervention: No laxative use
Number of subjects: 265
Study 37363965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib, Letrozole, and Palbociclib (TLP combination)
Number of subjects: 42
Study 37363989 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial VH interview
Number of subjects: 94
Study 37363989 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational VH interview
Number of subjects: 94
Study 37363989 — intervention group
Group type: COMPARATOR
Intervention: Standard VH interview
Number of subjects: 94
Study 37363992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab 500 mg every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression
Number of subjects: 314
Study 37363992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 314
Study 37364000 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate)
Number of subjects: 59
Study 37364000 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing (RNA-seq) analysis
Number of subjects: 59
Study 37364000 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) analysis
Number of subjects: 59
Study 37364000 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor pathway inhibitors (ARPI)
Number of subjects: 59
Study 37364000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AR activity, activation of stemness programs, and Hedgehog pathway
Number of subjects: 59
Study 37364000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired resistance
Number of subjects: 59
Study 37364004 — intervention group
Group type: EXPERIMENTAL
Intervention: DISCO App
Number of subjects: 0
Study 37364021 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training module for physician communication about clinical trials
Number of subjects: 19
Study 37364033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral-Based Hybrid Telerehabilitation Intervention (GOALS/Metas)
Number of subjects: 0
Study 37364033 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Physical Therapy
Number of subjects: 0
Study 37364044 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard plus timing and coordination training intervention
Number of subjects: 166
Study 37364044 — intervention group
Group type: COMPARATOR
Intervention: Standard strength and endurance intervention
Number of subjects: 166
Study 37364133 — intervention group
Group type: EXPERIMENTAL
Intervention: Teduglutide (0.05 mg/kg/day)
Number of subjects: 29
Study 37364133 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 29
Study 37364218 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with ramucirumab and paclitaxel
Number of subjects: 50
Study 37364220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment for high-risk colorectal cancer
Number of subjects: 1587
Study 37364220 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1587
Study 37364223 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent relacorilant + nab-paclitaxel
Number of subjects: 178
Study 37364223 — intervention group
Group type: COMPARATOR
Intervention: nab-paclitaxel monotherapy
Number of subjects: 178
Study 37364268 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour Time-Restricted Eating (TRE)
Number of subjects: 90
Study 37364268 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 90